Topic: alternative therapies for heart failure

In 2002, Cochrane Library reviewed randomized controlled trials utilizing TMS to treat depression. The evaluation didn't find a difference between rTMS and sham TMS, except for a interval 2 weeks after remedy. In 2018, Cochrane Library stated a plan to contact authors about updating the assessment of rTMS for depression. In August 2018, the US Food and Drug Administration (US FDA) authorized the usage of TMS developed by the Israeli company Brainsway in the remedy of obsessive-compulsive disorde...